- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07945314
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
A Phase 1, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
The main purpose of this study is to see if LY3839056 is safe and well tolerated when given as a single dose into a vein intravenous (IV) or under the skin subcutaneous (SC) in healthy participants. The study will also measure how much LY3839056 gets into the blood and how long it takes the body to remove it. The study will last up to 17 weeks and includes a stay of about 6 days at the clinical research unit.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: LillyTrials@lilly.com
Study Locations
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200040
- Huashan Hospital, Fudan University (复旦大学附属华山医院) 12 Urumqi Middle Road
-
Contact:
- Xiaojie Wu, PhD
- Phone Number: 13524686330
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and Cardiac Monitoring.
- Have clinical laboratory test results within normal reference range for the population or the clinical research site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.
- Have venous access sufficient to allow for IV drug delivery and blood sampling as per the protocol.
- Have a body mass index within the range of 18.0 to 32.0 kg/m².
- Participants assigned male or female at birth, including individuals of childbearing potential (IOCBP), may participate in this trial.
- Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Key Exclusion Criteria:
- Are immunocompromised or have a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection.
- Have a history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders.
- Had any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or any planned surgical procedure scheduled to occur during the study.
- Have a clinically significant history of multiple or severe allergies or an anaphylactic reaction to prescription or nonprescription drugs or food.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cohort 1 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Other Names:
|
|
Experimental: Cohort 2 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Other Names:
|
|
Experimental: Cohort 3 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Other Names:
|
|
Experimental: Cohort 4a IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Other Names:
|
|
Experimental: Cohort 4b SC
Participants will receive LY3839056 Subcutaneously |
LY3839056 Administered Subcutaneously
Other Names:
|
|
Experimental: Cohort 5 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Other Names:
|
|
Experimental: Cohort 6a IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Other Names:
|
|
Experimental: Cohort 6b SC
Participants will receive LY3839056 Subcutaneously |
LY3839056 Administered Subcutaneously
Other Names:
|
|
Placebo Comparator: Placebo IV
Participants will receive Placebo Intravenously |
Placebo Administered Intravenously
Other Names:
|
|
Placebo Comparator: Placebo SC
Participants will receive Placebo Subcutaneously |
Placebo Administered Subcutaneously
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the safety and tolerability of LY3839056 following single-dose administration (IV or SC) in healthy participants.
Time Frame: Baseline through Day 85
|
Frequency of AEs, TEAEs, SAEs, and Discontinuation due to TEAEs. |
Baseline through Day 85
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PK: Cmax
Time Frame: Predose on Day 1 up to Day 85
|
Maximum Observed Concentration (Cmax) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: AUC
Time Frame: Predose on Day 1 up to Day 85
|
Area Under the Concentration Versus Time Curve (AUC) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: t1/2
Time Frame: Predose on Day 1 up to Day 85
|
Half Life (t1/2) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: F%
Time Frame: Predose on Day 1 up to Day 85
|
Bioavailability (F%) of LY3839056 following single SC dose |
Predose on Day 1 up to Day 85
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 27924
- J7H-MC-KAAB (Other Identifier: Eli Lilly and Company)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.